Natera (NTRA) Q4 & FY2025 Results

Natera closed fiscal 2025 with a reported net loss of $208.2 million and a strengthened liquidity position of $1.076 billion in cash, cash equivalents and restricted cash. Operating cash flow improved materially to $215.3 million in 2025 from $135.7 million in 2024 and a negative $247.0 million in 2023, indicating improving cash generation from the business. Despite operating cash flow gains, the company remains cumulatively loss‑making with an accumulated deficit of approximately $2.8 billion at year end. Stock‑based compensation rose to $354.4 million in 2025, representing a meaningful non‑cash expense component. Depreciation and amortization totaled $41.8 million, and the company had $80.3 million outstanding under its credit facility at year‑end. The filings show product revenues dominate reported revenues (product revenues were 99.7% of total in Q3 2025, with Q3 product revenues of $590.2 million, +35% YoY), but the 10‑K/10‑Q disclosures do not provide a full segmented breakdown of FY product revenues.

Natera's commercial performance and outlook are driven principally by its flagship tests—Signatera (tumor‑informed ctDNA for MRD and recurrence monitoring), Panorama (NIPT), and Horizon (carrier screening)—which the company identifies as key revenue contributors for the foreseeable future. Growth catalysts cited in filings include scientific publications (170+ Signatera publications by 12/31/25), Medicare coverage expansions for certain indications, and recent M&A intended to broaden oncology MRD intellectual property (notably the Foresight Diagnostics transaction disclosed in December 2025). Filings also emphasize material risks investors should weigh. Regulatory uncertainty stemming from the FDA's post‑May 2024 LDT framework threatens increased compliance costs and potential timing risks for tests historically offered under enforcement discretion. Reimbursement remains a constraint: third‑party payers and Medicare coverage materially affect revenue collection (Medicare comprised 14.1% of accounts receivable in 2025). Operational exposures include reliance on single suppliers for key laboratory instruments and materials and concentration in a single reporting segment. The company also faces ongoing legal and IP risks and will need to manage costs and funding as it scales clinical adoption.

Key near‑term items for investors are the details and assumptions in the 2026 outlook included in the 8‑K, progress on reimbursement expansions for Signatera and Panorama, integration and realization of value from the December 2025 oncology/MRD acquisition(s), and execution against operating leverage targets given elevated stock‑based compensation and a substantial accumulated deficit. Monitor cash flow trends versus cash burn expectations and any changes to the credit facility or additional financing activity, as the company continues to invest in commercial scale and clinical validation.